Dyne Therapeutics Inc

DYN

Company Profile

  • Business description

    Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

  • Contact

    1560 Trapelo Road
    WalthamMA02451
    USA

    T: +1 781 786-8230

    E: [email protected]

    https://www.dyne-tx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    206

Stocks News & Analysis

stocks

Undervalued ASX share with plan to mitigate tariff risk

Shares have dropped 20% in the previous year due to concerns about tariffs.
stocks

Earnings up but shares overvalued for ASX gold miner

Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks

Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%

We see faster cloud growth and improved longer-term profitability for Alphabet.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,295.8026.20-0.28%
CAC 408,211.4427.74-0.34%
DAX 4024,278.7430.04-0.12%
Dow JONES (US)47,786.04241.450.51%
FTSE 1009,700.6746.850.49%
HKSE26,346.1487.56-0.33%
NASDAQ23,737.56100.100.42%
Nikkei 22550,219.18293.14-0.58%
NZX 50 Index13,402.6611.070.08%
S&P 5006,881.356.190.09%
S&P/ASX 2009,012.5016.30-0.18%
SSE Composite Index3,988.228.72-0.22%

Market Movers